CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 790 enrolled
Drug / intervention
VWF gene analysisgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02869074
NCT02869074N/ACompleted

Molecular and Clinical Profile of Von Willebrand Disease (VWD) in Spain (PCM-EVW-ES). Recruitment Extension, Further Data Analysis, Improvement of Registry Platform, Diagnosis and Management of VWD Application Development

Spanish Society of Thrombosis and Haemostasis·observational·Posted Aug 16, 2016·Updated Mar 12, 2025

In Brief

An observational study evaluating VWF gene analysis for Von Willebrand Disease. Completed, enrolled 790 participants across 1 site.

Detailed Summary

The present Project is a third phase of the previous PCM-EVW-ES Project (Batlle et al. Thromb \& Haemost 2015) with the aim of its extension, further analysis with an innovation development in the field of von Willebrand disease (VWD) based in the newer recently available methodologies. The aim of this project is to help the physician in a more uniform characterization and therapy of VWD in clinical practice, at an international level. A reduction of the expenses in the diagnosis process by using the new methodologies is pursued.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 16, 2016
Enrollment StartOct 3, 2017
Primary CompletionSep 25, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.9 years ago

Interventions

VWF gene analysisgenetic

52 exons adjacent intronic regions and promotor of VWF will be analyzed